The median effective dose (ED50) of remimazolam combined with remifentanil for procedural sedation in pediatric day-case circumcision

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400088209

Enrollment

Unknown

Registered

2024-08-13

Start date

2024-08-26

Completion date

Unknown

Last updated

2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pediatric prepuce

Interventions

Experimental group:remimazolam combined with remifentanil for procedural sedation

Eligibility

Sex/Gender

Male

Age

4 Years to 14 Years

Inclusion criteria

Inclusion criteria: ASA class I-II; Age 4-14 years; BMI = 35 kg/m²; Elective day case circumcision surgery; No history of epilepsy or other psychiatric disorders.

Exclusion criteria

Exclusion criteria: Contraindications to dorsal penile nerve block puncture; Comorbid severe congenital medical conditions; History of epilepsy or other psychiatric disorders; Preoperative administration of sedatives; Allergy to the study medications

Design outcomes

Primary

Measure	Time frame
MOAA/S;	—

Secondary

Measure	Time frame
Blood pressure, heart rate, pulse, oxygen saturation;Whether injection pain occurred;Satisfaction;	—

Countries

China

Contacts

Public ContactTiantian Liu

Ningbo University Affiliated Women and Children's Hospital

Liutiantian8385@163.com+86 137 3885 4907

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026